Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking With The NHS and other Healthcare OrganisationsCollaborative WorkingCollaborative Working Project between Norfolk and Norwich University Hospitals NHS Foundation Trust and Pfizer LimitedCollaborative Working Project between Norfolk and Norwich University Hospitals NHS Foundation Trust and Pfizer Limited
Nuclear medicine consultant, radiographer, radiography assistant, technical services pharmacist and a clinical nurse specialist - support to coordinate a 99mTc-DPD service for patients with suspected cardiac amyloidosis
Background
Cardiac amyloidosis (CA), particularly transthyretin cardiac amyloidosis (ATTR-CM), is increasingly recognised as a significant health concern. Accurate and early diagnosis is critical and the current options for patients in Norfolk requiring diagnosis of cardiac amyloidosis are limited. Norfolk does not have the specialist centres necessary to perform the full diagnostic workup as Norfolk and Norwich University Hospitals NHS Foundation Trust (NNUH) does not have provision for the required technetium-99m (99mTc) labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) Bone Scan element, preventing the uptake of this option for patients in Norfolk. Patients with ATTR-CM are often elderly with multiple co-morbidities making travel challenging.  Consequently, there is now a clear requirement to develop a network of expert regional centers for diagnosis. This project addresses diagnostic delays, fragmented care pathways, and health inequities, aligning with NHS Long Term Plan and Get It Right First Time (GIRFT) principles.
Project
The aim of the project is for NNUH to provide a comprehensive and efficient 99mTc-DPD scanning service for patients with suspected CA. This collaborative working initiative between NNUH and Pfizer Ltd aims to enhance CA care through the appointment of a Nuclear Medicine Consultant, Radiographer, Radiography assistant, Technical Services Pharmacist and a Clinical Nurse Specialist (CNS) would be important for setting up a service for a 99mTc-DPD bone scan where patients could get their full diagnostic workup locally to ensure timely diagnosis for patients with this progressive disease.

This project proposes funding for setting up a 99mTc-DPD Bone Scan service in the Nuclear Medicine Department at the NNUH.
Benefits
Benefits to patients
  • Faster access to diagnostics and treatment.
  • Standardised care pathways and reduced variation.
  • Enhanced clinical outcomes and quality of life.
  • Greater equity in access to diagnostic services.

Benefits to the NHS
  • Enhanced collaboration between NNUH and surrounding hospitals and the National Amyloidosis Centre (NAC).
  • Optimised resource use and reduced hospital admissions.
  • Expanded specialist knowledge and data collection.
  • Cost savings through earlier diagnosis and management.

Benefits to Pfizer
  • Suitable patients eligible for approved Pfizer treatments.
  • Insights into service delivery, patient needs, and MDT dynamics.
  • Enhanced understanding of resource utilisation for delivery of a diagnostic service for cardiac amyloidosis.
Potential Outcomes
  • Increase the number of patients screened and diagnosed.
  • Reduce time from referral to diagnosis and treatment.
  • Improve patient experience and reduce morbidity.
  • Reduction in health inequities and improved local access to diagnostic services.
  • Generate actionable audit data to support future NHS investment.
Proposed Term of the Collaborative Working Project
Planned start date: 1st December 2025.
Planned end date: 30th November 2026.
Resource Allocation
Pfizer Ltd will contribute:
  • Funding: £54,496.00
  • Human resource: £13,163.00
  • Total transfer of value: £67,659.00*
Pfizer will provide 100% of the staff funding upfront. 
 

*This is calculated as the sum of the direct financial contribution by Pfizer PLUS the benefit in kind value of the human resources provided by Pfizer


Norfolk and Norwich University Hospitals NHS Foundation Trust will contribute:
  • Funding: £49,000.00
  • Human resource: £19,146.00
  • Total: £68,146.00
ResponsibilityHealthcare Organisation Grants

Pfizer is committed to being transparent about the relationships we have with other organisations. 

PartnershipsDonations and Grants

Find out about the donations and grants we make available to support healthcare, scientific research and education.

PP-UNP-GBR-13674 / November 2025
Science Products Responsibility Partnerships Careers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2025 Pfizer Limited. PP-UNP-GBR-13382  / September 2025. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427.  This website is intended for the general public in the UK.